Journal of Antimicrobial Chemotherapy (2002) 50, 383-391
© 2002 The British Society for Antimicrobial Chemotherapy
Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features
1 Service de Microbiologie, 2 Unité d’Epidémiologie et d’Hygiène Hospitalière and 3 Service de Pneumologie, Hôpital Erasme, Université Libre de Bruxelles, 808 route de Lennik, 1070 Brussels, Belgium; 4 Hôpital Edouard Herriot, Université Claude Bernard, Lyon, France
Received 13 May 2002; accepted 10 June 2002
In 1999, all clinical Staphylococcus aureus isolates from patients admitted to a Belgian University hospital were tested for decreased vancomycin susceptibility. Three vancomycin-intermediate Staphylococcus aureus (VISA) and four hetero-VISA strains were detected among 2145 isolates tested. They emerged from strains that belonged to locally endemic methicillin-resistant S. aureus (MRSA) genotypes in three patients who had received repeated courses of vancomycin therapy. A cystic fibrosis patient with MRSA/VISA-associated broncho-pulmonary exacerbation was successfully treated by continuous vancomycin infusion plus fusidic acid followed by oral minocycline–fusidic acid. Two other patients had VISA recovered from specimens of undetermined clinical significance. Emergence of VISA variants of endemic MRSA strains in Belgium warrants active microbiological surveillance and careful monitoring of vancomycin therapy. Therapy with high-dose vancomycin administered by continuous infusion in combination with other antimicrobials may be a therapeutic option worth investigating for VISA infection.
Keywords: Staphylococcus aureus, VISA, Belgium, vancomycin
* Corresponding author. Tel: +32-2-555-45-18; Fax: +32-2-555-31-10; E-mail: odenis{at}ulb.ac.be
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. P. Howden, J. K. Davies, P. D. R. Johnson, T. P. Stinear, and M. L. Grayson Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications Clin. Microbiol. Rev., January 1, 2010; 23(1): 99 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Renzoni, W. L. Kelley, C. Barras, A. Monod, E. Huggler, P. Francois, J. Schrenzel, R. Studer, P. Vaudaux, and D. P. Lew Identification by Genomic and Genetic Analysis of Two New Genes Playing a Key Role in Intermediate Glycopeptide Resistance in Staphylococcus aureus Antimicrob. Agents Chemother., March 1, 2009; 53(3): 903 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Robert, R. Bismuth, and V. Jarlier Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002 J. Antimicrob. Chemother., March 1, 2006; 57(3): 506 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. J. Brown, D. I. Edwards, P. M. Hawkey, D. Morrison, G. L. Ridgway, K. J. Towner, M. W. D. Wren, and on behalf of the Joint Working Party of the Britis Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA) J. Antimicrob. Chemother., December 1, 2005; 56(6): 1000 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sancak, S. Ercis, D. Menemenlioglu, S. Colakoglu, and G. Hascelik Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital J. Antimicrob. Chemother., September 1, 2005; 56(3): 519 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Faber, R. J. W. Hoogendoorn, H. P. Stallmann, D. M. Lyaruu, A. van Nieuw Amerongen, P. I. J. M. Wuisman, and on behalf of STEGA (Skeletal Tissue Engineering Gr In vivo comparison of Dhvar-5 and gentamicin in an MRSA osteomyelitis prevention model J. Antimicrob. Chemother., December 1, 2004; 54(6): 1078 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Weiss, T. Murphy, E. Lenoy, and M. Young In Vivo Efficacy and Pharmacokinetics of AC98-6446, a Novel Cyclic Glycopeptide, in Experimental Infection Models Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1708 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jabes, G. Candiani, G. Romano, C. Brunati, S. Riva, and M. Cavaleri Efficacy of Dalbavancin against Methicillin-Resistant Staphylococcus aureus in the Rat Granuloma Pouch Infection Model Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1118 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Verdier, M.-E. Reverdy, J. Etienne, G. Lina, M. Bes, and F. Vandenesch Staphylococcus aureus Isolates with Reduced Susceptibility to Glycopeptides Belong to Accessory Gene Regulator Group I or II Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1024 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. El Solh, M. Davi, A. Morvan, H. A. Damon, N. Marty, and the other members of the GISA group, RAISIN subgro Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides J. Antimicrob. Chemother., October 1, 2003; 52(4): 691 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Byl, F. Jacobs, P. Wallemacq, C. Rossi, P. de Francquen, M. Cappello, T. Leal, and J.-P. Thys Vancomycin Penetration of Uninfected Pleural Fluid Exudate after Continuous or Intermittent Infusion Antimicrob. Agents Chemother., June 1, 2003; 47(6): 2015 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Van Griethuysen, A. Van 't Veen, A. Buiting, T. Walsh, and J. Kluytmans High Percentage of Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Glycopeptides in The Netherlands J. Clin. Microbiol., June 1, 2003; 41(6): 2487 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Faber, H. P. Stallmann, D. M. Lyaruu, J. M. A. de Blieck, Th. J. M. Bervoets, A. van Nieuw Amerongen, and P. I. J. M. Wuisman Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads J. Antimicrob. Chemother., June 1, 2003; 51(6): 1359 - 1364. [Abstract] [Full Text] [PDF]
|
|